Chartwell Investment Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Chartwell Investment Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,535	Closed	-$1.15M	–	440
2023 Q1	$1.15M	Sell	10,535 -12,517	-54%	-$1.38M	0.04%	332
2022 Q4	$2.62M	Sell	23,052 -90,039	-80%	-$7.48M	0.1%	243
2022 Q3	$7M	Sell	113,091 -32,677	-22%	-$2.28M	0.3%	118
2022 Q2	$11.6M	Buy	145,768 +1,885	+1%	+$179K	0.47%	59
2022 Q1	$15.1M	Buy	143,883 +13,778	+11%	+$1.34M	0.5%	49
2021 Q4	$14M	Sell	130,105 -1,048	-0.8%	-$114K	0.41%	82
2021 Q3	$14.4M	Sell	131,153 -4,261	-3%	-$442K	0.45%	74
2021 Q2	$12.7M	Buy	135,414 +6,672	+5%	+$614K	0.37%	103
2021 Q1	$11.8M	Sell	128,742 -4,116	-3%	-$347K	0.35%	110
2020 Q4	$9.72M	Sell	132,858 -6,554	-5%	-$487K	0.31%	129
2020 Q3	$10.8M	Sell	139,412 -42,808	-23%	-$2.95M	0.4%	92
2020 Q2	$10.1M	Sell	182,220 -27,729	-13%	-$1.19M	0.39%	95
2020 Q1	$6.22M	Buy	209,949 +63,721	+44%	+$2.16M	0.29%	129
2019 Q4	$5.29M	Sell	146,228 -87,692	-37%	-$2.69M	0.17%	187
2019 Q3	$6.37M	Buy	233,920 +66,878	+40%	+$1.73M	0.21%	179
2019 Q2	$4.02M	Buy	167,042 +83,904	+101%	+$2.13M	0.13%	227
2019 Q1	$2.2M	Buy	+83,138	New	+$1.97M	0.07%	318
2016 Q4	–	Sell	-141,450	Closed	-$2.56M	–	454
2016 Q3	$2.56M	Buy	+141,450	New	+$2.76M	0.05%	327
2016 Q1	–	Sell	-455,130	Closed	-$9.86M	–	343
2015 Q4	$9.86M	Sell	455,130 -330	-0.1%	-$6.42K	0.2%	155
2015 Q3	$9.03M	Sell	455,460 -5,650	-1%	-$179K	0.19%	165
2015 Q2	$16M	Sell	461,110 -1,247,770	-73%	-$38.1M	0.31%	108
2015 Q1	$44.4M	Buy	+1,708,880	New	+$31.3M	0.86%	24
2014 Q4	–	Sell	-1,287,853	Closed	-$15.8M	–	384
2014 Q3	$15.8M	Buy	1,287,853 +306,740	+31%	+$3.56M	0.36%	102
2014 Q2	$15.5M	Sell	981,113 -119,207	-11%	-$1.7M	0.32%	129
2014 Q1	$16.6M	Buy	+1,100,320	New	+$12.4M	0.34%	116

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Chartwell Investment Partners's HZNP Position: Q2 2023 in Review

Chartwell Investment Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 10,535 shares — an estimated $1.15M sold.

Chartwell Investment Partners first reported a position in HZNP in Q1 2014 and held it in 25 quarters. The position peaked at $44.4M in Q1 2015. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Chartwell Investment Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Chartwell Investment Partners sold 10,535 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $1.15M.
Chartwell Investment Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 25 quarters.
Chartwell Investment Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $44.4M in Q1 2015.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Chartwell Investment Partners's 13F filing for Q2 2023, filed 25 Jul 2023.